Figure 2
Inhibition of Hsp70 affects Tcl1 expression. (A) Daudi lymphoma cells were treated with the Hsp70 inhibitor Myr, 17AAG, Hsp70 activator SWO2, and combinations as indicated for 6 and 12 hours. Cells were lysed and protein extracts were subjected to SDS-PAGE and analyzed by Western blotting with indicated antibodies. The numbers above the blots indicate the intensity of the band expressed as ratio gene product (TCL1, HSP70, or AKT1)/GAPDH and normalized to Mock 6 hours or Mock 12 hours. (B) Daudi lymphoma cells were treated with 17AAG (5μM), Myr (50μM), and their combination for 24 hours, with or without Etoposide (40μM) for 12 hours. Cells lysates were analyzed by Western blotting with indicated antibodies. The numbers above the blots indicate the intensity of the band expressed as ratio gene product (p-AKT1, HSP70)/GAPDH and normalized to Mock or Mock-Etoposide.

Inhibition of Hsp70 affects Tcl1 expression. (A) Daudi lymphoma cells were treated with the Hsp70 inhibitor Myr, 17AAG, Hsp70 activator SWO2, and combinations as indicated for 6 and 12 hours. Cells were lysed and protein extracts were subjected to SDS-PAGE and analyzed by Western blotting with indicated antibodies. The numbers above the blots indicate the intensity of the band expressed as ratio gene product (TCL1, HSP70, or AKT1)/GAPDH and normalized to Mock 6 hours or Mock 12 hours. (B) Daudi lymphoma cells were treated with 17AAG (5μM), Myr (50μM), and their combination for 24 hours, with or without Etoposide (40μM) for 12 hours. Cells lysates were analyzed by Western blotting with indicated antibodies. The numbers above the blots indicate the intensity of the band expressed as ratio gene product (p-AKT1, HSP70)/GAPDH and normalized to Mock or Mock-Etoposide.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal